Celator joins leukemia society for phase II trial of CPX-351

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

Celator Pharmaceuticals and the Leukemia & Lymphoma Society have partnered for the phase II development of CPX-351 (cytarabine:daunorubicin), a liposome injection for treatment of adults with acute myeloid leukemia.

Celator Pharmaceuticals and the Leukemia & Lymphoma Society have partnered for the phase II development of CPX-351 (cytarabine:daunorubicin), a liposome injection for treatment of adults with acute myeloid leukemia.

Through the partnership, the society will provide $3.7 million to support the multicenter, randomized, open-label trial of CPX-351 compared with intensive salvage therapy in adult patients (≤ 60 years of age) with AML in first relapse. Celator expects to start patient enrollment in this study in the first quarter of 2009 in the U.S. and Canada. CPX-351 has also been granted orphan drug status by the FDA for the treatment of AML.

The collaboration is part of the society’s Therapy Acceleration Program, which supports private sector and academic-based projects that advance investigational therapies.

Recent Videos
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.